Longevity & AgingResearch PaperPaywall

Multi-omics and AI are redefining how scientists measure biological age

A new review shows how genomic, epigenetic, proteomic, metabolomic and microbiome data, plus AI, may enable personalized biological age tracking and healthy ageing.

Saturday, November 14, 2026 0 views
Published in Ageing Res Rev
Translucent human silhouette with layered glowing DNA, protein, metabolite and gut microbiome data streams converging into a digital clock face.

Summary

Chronological age tells only part of the story about how well someone is ageing. This review examines how high-throughput omics technologies, which measure millions of biomolecules from a single sample, are being used to define and track biological age. The authors cover genomics, epigenomics, proteomics, metabolomics and microbiomics. They describe longevity-associated genetic variants, epigenetic clocks that predict biological age, blood proteome scores that can reflect organ- and sex-specific ageing, metabolite signatures, and emerging gut microbiome clocks. The review also notes that exercise and diet studies using omics readouts suggest interventions can lower biological age. Looking ahead, the authors argue that combining multi-omics with clinical and lifestyle data through machine learning and AI could produce a more holistic definition of biological age and support personalized healthy ageing strategies.

Detailed Summary

Ageing is a complex, multifactorial process, and no single biomarker captures it. Chronological age is a poor proxy for functional decline, so researchers are looking for molecular measures of biological age that could guide prevention and evaluate anti-ageing interventions.

This narrative review synthesizes recent work applying genomics, epigenomics, metabolomics and microbiomics to ageing research, with discussion of blood proteomics as well. It focuses on how each layer contributes to biomarker discovery, mechanistic insight and translational potential. Only the abstract was available for this summary, so details of the studies cited are not covered here.

According to the abstract, genomic studies have identified variants associated with extreme longevity, and epigenetic clocks are described as robust predictors of biological age. Blood proteome scores can track ageing trajectories over time in organ- and sex-specific ways. Metabolomic signatures point to metabolites that reflect ageing trajectories. Gut microbiome composition appears both to mirror and to modulate biological ageing, and microbiome clocks are emerging. Omics-based studies of exercise and diet also suggest that interventions can reduce measured biological age.

The authors propose that integrating multi-omics data with clinical and lifestyle information, using machine learning and AI, could yield a more holistic definition of biological age. That in turn could support personalized healthy-ageing strategies and better ways to monitor whether interventions work.

Caveats apply. This is a review, not a new trial, and the abstract gives no effect sizes, cohort details or validation data. A reduction in a biological age score does not necessarily mean better health outcomes or longer life. Standardization, reproducibility and clinical validation of these clocks remain open questions.

Key Findings

  • Epigenetic clocks are described as robust predictors of biological age across the omics layers reviewed.
  • Blood proteome scores can track ageing trajectories in an organ- and sex-specific manner.
  • Gut microbiome composition mirrors and may modulate biological ageing, and microbiome clocks are emerging.
  • Omics studies suggest exercise and diet can reduce measured biological age.
  • Machine learning integration of multi-omics, clinical and lifestyle data may enable a holistic, personalized biological age definition.

Methodology

This is a narrative review synthesizing recent literature on genomics, epigenomics, proteomics, metabolomics and microbiomics in ageing research. The abstract does not describe a systematic search strategy, inclusion criteria or quantitative synthesis. Only the abstract was available for this analysis.

Study Limitations

The abstract provides no quantitative data, so the strength and consistency of evidence for each omics layer cannot be judged. Evidence that interventions reduce biological age does not establish that they improve clinical outcomes or lifespan. Standardization, population generalizability and clinical validation of these clocks remain unresolved.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: